President Trump’s bold drug pricing deals have slashed costs for GLP-1 weight loss drugs and fertility treatments by half, delivering real relief to American families battered by years of skyrocketing healthcare expenses.
Story Highlights
- GLP-1 drugs like Ozempic and Wegovy are now available at roughly half price through TrumpRx.gov, dropping from over $1,000 to $199- $350 per month for cash-paying patients.
- Fertility medications such as Gonal-F cut to $168 per pen, Cetrotide to $22.50, saving over $2,000 per IVF cycle—vital for families seeking to build without insurance barriers.
- Trump administration leverages most-favored-nation pricing and tariff exemptions to force manufacturers like Eli Lilly, Novo Nordisk, and EMD Serono into historic discounts.
- TrumpRx.gov, launched in February 2026, lists 54 drugs, fulfilling a promise to curb out-of-pocket costs amid top voter concerns about healthcare affordability.
- Medicare Director Chris Klomp confirms these wins reverse Biden-era failures, enabling broader access for diabetes, obesity, and infertility treatments.
TrumpRevives Drug Pricing Wins from First Term
In 2025, President Trump revived his first-term strategies by announcing an agreement with EMD Serono for most-favored-nation pricing on IVF drugs such as Gonal-F, Cetrotide, and Ovidrel.
This deal offered an 84% discount via TrumpRx.gov in exchange for tariff exemptions and domestic manufacturing commitments.
The White House launched the platform in February 2026, directly targeting high costs that left 25% of Americans unable to afford prescriptions.
Surging demand for GLP-1 drugs had pushed list prices above $1,000 monthly, while fertility cycles ran $3,000-$7,000 without coverage.
These executive actions contrast sharply with blocked efforts from 2020 and Biden’s narrower Medicare negotiations.
Massive Savings on GLP-1 and Fertility Drugs
Medicare Director Chris Klomp stated on Fox Business that GLP-1 prices halved a couple of months ago under Trump deals, extending savings to fertility meds and saving thousands per treatment cycle.
TrumpRx.gov now offers Gonal-F at $168 per pen, down from higher list prices; Cetrotide from $316 to $22.50; and Ovidrel from $251 to $84, totaling over $2,000 savings per IVF cycle for cash-paying patients.
GLP-1s like Wegovy start at $199 for initial fills via the platform, with Medicare alignment at $245 monthly and direct-to-consumer vials at $350—30% below manufacturer direct prices.
Eli Lilly and Novo Nordisk agreed to these terms, including future oral options at $150.
Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp
— FOX Business (@FoxBusiness) April 7, 2026
Stakeholders Align Behind Affordability Push
President Trump’s architects created TrumpRx.gov, with CMS Director Klomp overseeing implementation and touting results showing that a quarter of Americans skip scripts due to cost.
Manufacturers like Eli Lilly, Novo Nordisk for GLP-1s (Zepbound, Mounjaro, Wegovy, Ozempic), and EMD Serono for IVF drugs offer trade discounts for tariff avoidance and access to Medicare obesity coverage.
The administration wields MFN pricing—aligning U.S. costs to the lowest international rates—and tariff threats to secure volume boosts and domestic production.
Patients gain lower out-of-pocket costs for uninsured needs, while Medicare and Medicaid enforce pricing over 24 months. Critics note scope limits, but official listings confirm factual price drops.
TrumpRx.gov, operational as of March 2026, lists 54 drugs, including insulin at $25, though some introductory GLP-1 discounts like Wegovy’s $199 rise to $349 post-spring.
Thirteen states now cover GLP-1 obesity treatments under Medicaid, with strict refill rules, such as 45-day limits on Zepbound.
AMCP highlights MFN-enabling coverage but flags autoinjector uncertainties for vials; ASRM praises IVF discounts yet points to gaps in full-cycle support. These steps incentivize direct-to-consumer sales and compete with coupons, prioritizing American families over big pharma profits and globalist pricing schemes.
Real Impacts for Families and Economy
Cash-paying patients see immediate relief: $2,000+ per IVF cycle and GLP-1 access at $245 Medicare or $350 DTC, aiding 22 million with obesity or diabetes. Fertility seekers, often privately insured yet uncovered, benefit from targeted cuts reversing insurance voids.
Economically, the platform saves pharmacy dollars and bolsters Medicare sustainability through leverage.
Socially, it boosts family-building and weight management without government overreach. Politically, it fulfills Trump’s promises, countering past fiscal mismanagement and woke distractions.
Long-term, MFN could expand, though the current scale covers select high-demand drugs among thousands available.
Sources:
Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s
TrumpRx drugs website discount
Trump wrong drug pricing state union
